Long-Term Tirzepatide Demonstrates Benefits in Patients With CKD, Obesity, and HFpEF
April 7th 2025Tirzepatide-treated patients with chronic kidney disease (CKD), obesity, and heart failure with preserved ejection fraction (HFpEF) had improved renal function both by cystatin C and creatinine.
Read More
AAN 2025: GLP-1 Analogues' Promise in Alzheimer Disease Treatment
April 7th 2025Glucagon-like peptide-1 (GLP-1) analogs demonstrate potential to address multiple pathological processes in Alzheimer disease, with promising early research suggesting cognitive improvements and potential for future treatment.
Watch
AAN 2025: Pharmacists Key Players in Safe, Effective Migraine Treatment With CGRP Antagonists
April 7th 2025Andrew Charles, MD, outlines why calcitonin-gene-related peptide (CGRP) antagonists are increasingly favored as first-line migraine treatments and how pharmacists play a key role in patient education and support.
Watch
AAN 2025: Specialty Pharmacists Improve Outcomes in Non-MS Clinics With High-Impact Interventions
April 6th 2025A study led by Kayla Johnson, PharmD, BCPS, BCPP found that integrating specialty pharmacists into non-multiple sclerosis (MS) neurology clinics led to significantly enhanced patient care and treatment outcomes.
Watch
How Microbial Preservation Supports Quality and Safety in Compounding Pharmacies
April 4th 2025Mark Mulvahill, MBA, MSc, discusses the importance of microbial preservation and reference materials in pharmaceutical manufacturing and compounding pharmacies, highlighting their role in contamination control, regulatory compliance, and enhancing microbiological testing reliability.
Read More
Rilzabrutinib Granted Orphan Drug Designation For Multiple Rare, Immune-Mediated Conditions
April 4th 2025The new designations span both warm autoimmune hemolytic anemia and IgG4-related disease, 2 rare, immune-mediated conditions that burden patients due to a lack of available treatment options.
Read More
FDA Grants Accelerated Approval to Atrasentan for Proteinuria Reduction in Primary IgA Nephropathy
April 3rd 2025Positive results from an interim analysis of the phase 3 ALIGN study bolstered atrasentan towards receiving accelerated approval for patients with immunoglobulin A nephropathy, a rare condition that can cause kidney failure.
Read More
ELCC 2025: Amivantamab Plus Lazertinib Effective in EGFR-Mutated NSCLC Versus Standard of Care
April 2nd 2025Nicolas Girard, MD, explains the benefits observed in the MARIPOSA clinical trial among patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated with amivantamab plus lazertinib.
Watch